Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Protalix BioTherapeutics (PLX) Tops Q3 EPS by 8c
November 14, 2022 6:54 AM ESTProtalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.7 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
... More